Novartis jobs deal: Swiss corporate leverage, people power or prior laziness?
This article was originally published in Scrip
The power wielded by Novartis in its home country of Switzerland was apparently made clear this week when the company managed to secure a tailor-made tax deal in exchange for not cutting 330 jobs at one of its local plants. However – and with the deal shrouded in secrecy it is difficult to be sure – it may say less about Novartis's indisputable importance to the Swiss economy and employment, and more about the multinational's lack of attention to detail last year. On the other hand, it may more straightforwardly show what can be achieved when a company opens a pro-active dialogue with staff and other stakeholders.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.